https://pharminent.com/partners-bizengri-cleared-by-fda-for-ultra-rare-cancer-days-after-winning-priority-voucher/ 2026-05-11T16:00:22Z Pharminent en Partner's Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher 2026-05-11T11:23:25Z Blog https://pharminent.com/deal-finally-unlocks-nhs-access-to-itfs-duchenne-drug/ 2026-05-11T16:00:25Z Pharminent en Deal finally unlocks NHS access to ITF's Duchenne drug 2026-05-11T11:17:05Z Blog https://pharminent.com/bms-sotyktu-secures-ec-approval-for-psoriatic-arthritis-2/ 2026-05-11T16:00:28Z Pharminent en BMS' Sotyktu secures EC approval for psoriatic arthritis 2026-05-11T08:32:52Z Blog https://pharminent.com/pulsesight-reports-positive-phase-1-data-for-pst611-in-dry-amd/ 2026-05-11T16:00:29Z Pharminent en Pulsesight reports positive phase 1 data for PST611 in dry AMD 2026-05-11T07:34:05Z Blog https://pharminent.com/80442-2/ 2026-05-10T17:35:21Z Pharminent en 2026-05-10T17:34:15Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-may-9-2026/ 2026-05-10T15:27:29Z Pharminent en Week in Review • INTELLIGENCE BRIEF • May 9, 2026 2026-05-10T15:27:26Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-8-2026/ 2026-05-09T01:34:42Z Pharminent en Oncology Intelligence Digest • May 8, 2026 2026-05-09T01:34:38Z Blog